STAT Stitch Deep Dive Podcast Beyond The Bedside

CC Nurse | Fluid and Electrolyte Balance

Fluid Compartments & Homeostasis Distribution: Water is 50%–60% of adult weight (varies with fat). ICF holds 2/3 of water; ECF holds 1/3 (interstitial fluid/plasma). Weight change is the best fluid shift indicator (1 kg = 1 L). Capillary Exchange: Governed by hydrostatic (pushes out) and plasma oncotic (albumin pulls in) pressures. Edema occurs if hydrostatic pressure rises, oncotic falls, or lymphatics are blocked. Third-spacing traps nonfunctional fluid. Regulatory Mechanisms Hormones: Dehydration triggers thirst and pituitary ADH, raising renal water reabsorption. Aldosterone promotes sodium retention and potassium excretion. Atrial stretch releases natriuretic peptides (ANP/BNP) to excrete sodium/water. Electrolytes & Clinical Imbalances Sodium (136–145 mEq/L): Governs ECF osmolality (280–295 mOsm/kg) and impacts CNS. Hypernatremia (>145 mEq/L) causes cell shrinkage; rapid correction risks cerebral edema. Hyponatremia (<136 mEq/L) causes cell swelling; rapid correction risks osmotic demyelination. Potassium (3.5–5.0 mEq/L): Dictates membrane potentials. Hyperkalemia (>5.0 mEq/L) causes peaked T waves, wide QRS, and arrest. Treatment: stop intake, diuretics/binders, shift K+ with insulin/beta-agonists, and stabilize heart with IV calcium. Hypokalemia (<3.5 mEq/L) causes flat T waves, U waves, and weakness. IV KCl must be diluted, infused slowly (<10 mEq/hr), and never pushed. Divalent Cations: Calcium (9.0–10.5 mg/dL) is regulated by PTH and calcitonin. Hypercalcemia sedates nerves/muscles; hypocalcemia causes tetany with positive Chvostek/Trousseau signs. Magnesium (1.3–2.1 mEq/L) is vital for ATP. Hypomagnesemia (<1.3 mEq/L) resembles hypocalcemia, causing hyperactive reflexes and torsades. Acid-Base Balance (pH 7.35–7.45) Regulated by buffers, lung CO2 excretion, and renal bicarbonate/H+ control: Respiratory Acidosis: Carbonic acid excess from hypoventilation (CO2 retention). Respiratory Alkalosis: Carbonic acid deficit from hyperventilation (CO2 depletion). Metabolic Acidosis: Bicarbonate deficit or acid buildup; anion gap is 8–12 mmol/L. Metabolic Alkalosis: Bicarbonate excess or acid loss (vomiting/NG suction). Crystalloid Solutions Tonicity Effects: Hypotonic (e.g., 0.45% NaCl) dilutes ECF, swelling cells to treat hypernatremia. Isotonic (e.g., 0.9% NaCl, Lactated Ringer's) expands ECF volume without shifts. Hypertonic (e.g., 3.0% NaCl) draws water out of cells to treat hyponatremia.

CC Nurse | ARDS & ARF

Acute Respiratory Failure (ARF) and Acute Respiratory Distress Syndrome (ARDS) are critical pulmonary conditions where gas exchange is insufficient to support systemic organs1. The 80/20 Core: Pathophysiology & Clinical Care 1. Classification of ARF ARF is a symptom of inadequate lung function, categorized into two types12: Hypoxemic (Oxygenation Failure): $PaO_2 < 60$ mm Hg on room air2. The core defect is inadequate $O_2$exchange, caused by $V/Q$ mismatch, shunt, diffusion impairment, or alveolar hypoventilation23. Shunt is an extreme mismatch where alveoli fill with fluid, making $O_2$ therapy alone ineffective45. Hypercapnic (Ventilatory Failure): $PaCO_2 > 50$ mm Hg with $pH < 7.35$6. It represents insufficient $CO_2$ removal6. Primary causes include CNS depression, neuromuscular disease, chest wall abnormalities, or airway obstruction (COPD, severe asthma)7more_horiz. 2. ARDS Pathophysiology & Phases ARDS is a progressive form of ARF triggered by direct or indirect lung injury11more_horiz. Its hallmark is refractory hypoxemia—unresponsive to supplemental oxygen1415. It progresses in three phases16: Injury/Exudative (24–72 hours): Inflammatory mediators damage the membrane, causing edema1617. Alveolar type II cells are damaged, reducing surfactant, which causes collapse (atelectasis) and stiff lungs1819. Reparative/Proliferative (1–2 weeks): Fibroblasts and inflammatory cells infiltrate, increasing resistance, causing pulmonary hypertension and decreased compliance20. Fibrotic/Late Phase: Diffuse scarring and remodeling further reduce gas exchange surface area, correlating with a poor prognosis21. 3. Interprofessional Management Treatment focuses on treating causes, optimizing gas exchange, and avoiding complications122: Ventilation Support: BiPAP decreases the work of breathing (WOB) in mild ARF23. Severe ARDS requires low tidal volume ($V_T$) ventilation (4–8 mL/kg) to prevent barotrauma/volutrauma24. This causes permissive hypercapnia (allowing $PaCO_2$ up to 60 mm Hg if $pH \ge 7.30$)2526. High PEEP is applied to recruit collapsed alveoli27. Prone Positioning: For severe ARDS with refractory hypoxemia; turning patients prone recruits dorsal alveoli, improving $V/Q$ matching28. Supportive Care: Corticosteroids reduce airway inflammation2930. Fluid management keeps patients "on the dry side" to minimize pulmonary edema31. Enteral nutrition should begin within 24–48 hours to preserve respiratory muscle mass32.

CC Nurse | Respiratory Obstructive Complications

Core Concept: Expiratory Airflow Resistance Obstructive lung diseases—bronchiectasis, cystic fibrosis (CF), asthma, and COPD—share increased expiratory airflow resistance from airway obstruction or narrowing. Drug therapy plays a key role in their clinical management. 1. Bronchiectasis: Mucus Stasis Pathophysiology & Presentation: Inflammation destroys elastic and muscular wall structures, causing permanent dilation and impaired mucus clearance. It presents as a persistent cough with thick, purulent sputum. Massive hemoptysis is a life-threatening complication. Care: CT scan is the gold standard. Care involves antibiotics (minimum 14 days), bronchodilators, and ACTs with hydration (2-3 L/day). 2. Cystic Fibrosis (CF): Ion Transport Defect Pathophysiology & Presentation: An autosomal recessive CFTR mutation disrupts sodium and chloride transport, producing thick, dehydrated mucus that plugs respiratory, GI, and reproductive ducts. This causes progressive organ scarring, pancreatic insufficiency, and malabsorption. Care: Sweat chloride testing is the gold standard. Management relies on aggressive ACTs and mucus-liquefying medications (dornase alfa), combined with pancreatic enzyme replacement before meals and mutation-specific CFTR modulators. 3. Asthma: Reversible Airflow Hyperreactivity Pathophysiology & Presentation: Inflammation involves mast cells and eosinophils. Triggers cause an early IgE-mediated bronchospasm, often followed by a late-phase response 4-6 hours later. Signs include wheezing, dyspnea, and cough. A sudden absence of wheezing ("silent chest") is an emergency. Care: Spirometry confirms reversibility (>12% and >200 mL FEV1 improvement post-bronchodilator). Inhaled corticosteroids (ICS) are first-line anti-inflammatories, often paired with LABAs. SABAs provide rescue relief, and patients follow an Asthma Action Plan based on peak flow zones. 4. COPD: Progressive Airflow Limitation Pathophysiology & Presentation: Non-reversible airflow limitation is driven by chronic exposure to toxins, mainly smoking. Inflammation causes alveolar destruction (emphysema), goblet cell hyperplasia, and loss of elastic recoil. It presents with progressive exertional dyspnea, chronic cough, and a "barrel chest". Care: Diagnosed when post-bronchodilator FEV1/FVC is <70%. Key care includes smoking cessation and stepwise inhaled drugs (LAMAs, LABAs, ICS). Calorie-dense nutrition combats cachexia, while pursed-lip breathing reduces air trapping.

CC Nurse | Lower Respiratory Complications

This summary distills the 20% of core clinical concepts driving 80% of patient outcomes, grounded directly in the provided material. 1. Lower Respiratory Infections: Pneumonia & Tuberculosis (TB) Pneumonia: Acute lung parenchymal infection where pathogens invade via aspiration, inhalation, or blood. Inflammation increases vascular permeability, causing capillary leakage and alveolar fluid consolidation, impairing gas exchange. Clinical Rule: Initiate empiric antibiotic therapy immediately upon suspicion to reduce mortality; adjust only after culture results. Prevent aspiration pneumonia by elevating the head of the bed to ≥30° and checking the gag reflexes. Tuberculosis (TB): Airborne disease caused by M. tuberculosis. LTBI vs. Active TB: Latent TB (LTBI) is asymptomatic, non-infectious, has normal chest x-rays, and requires single-drug therapy (e.g., isoniazid). Active TB is infectious, symptomatic, and treated with a 4-drug regimen (isoniazid, rifampin, pyrazinamide, ethambutol). Clinical Priority: Due to the rise of multidrug-resistant strains (MDR-TB), Directly Observed Therapy (DOT) is the standard of care for non-adherent patients. 2. Acute Pleural & Trauma Emergencies Tension Pneumothorax: A life-threatening emergency where air enters the pleural space on inspiration but cannot escape, causing positive pressure, lung collapse, and mediastinal shift that compresses the heart and unaffected lung. Manifestations: Severe dyspnea, tachycardia, and tracheal deviation. Requires immediate needle decompression and chest tube insertion. Flail Chest: Fracture of ≥3 consecutive ribs in ≥2 places, causing paradoxical chest wall movement (moves inward during inspiration, outward during expiration). Treat with oxygen, analgesics, and positive pressure ventilation to stabilize the segment. 3. Vascular & Blockage Emergencies: Pulmonary Embolism (PE) Pathophysiology: Blockage of pulmonary arteries by a thrombus (usually from lower-limb DVT), obstructing alveolar perfusion. Diagnosis & Management: Dyspnea is the most common symptom. A spiral CT scan is the gold standard for diagnosis (or V/Q scan if contrast is contraindicated). Key Care: Administer immediate anticoagulation (LMWH or IV heparin) to prevent clot extension; long-term therapy (e.g., warfarin) continues for ≥3 months. 4. Oncologic Malignancies: Lung Cancer NSCLC vs. SCLC: Non-Small Cell (84%) grows moderately and is treated surgically if diagnosed in early stages (I–IIIA). Small Cell (SCLC, 13%) is highly aggressive, spreads early via blood and lymph (frequently to the brain), and is treated primarily with systemic chemotherapy and prophylactic cranial irradiation.

• Transcript

CC Nurse | Supporting Ventilation

I. Oxygen Therapy & Delivery Systems Target: Maintain SpO2 >92% (or >88% in chronic COPD) or PaO2 >60 mmHg. Supplementing FiO2 >60% for >24 hours risks oxygen toxicity, causing severe pulmonary edema and inflammatory alveolar damage. Low-Flow Systems: Nasal Cannula (1–6 L/min, 24%-44% FiO2), Simple Mask (6–12 L/min, 35%-50% FiO2, requires >=6 L/min), Non-Rebreather (10–15 L/min, 60%-90% FiO2, keep reservoir bag inflated). High-Flow Systems: Venturi Mask (delivers precise, fixed FiO2 for COPD), High-Flow Nasal Cannula (up to 60 L/min, 100% FiO2, heated humidification). CO2 Narcosis: Some COPD patients lose sensitivity to high CO2, relying on a hypoxic drive to breathe. However, never withhold oxygen during severe, life-threatening hypoxemia. II. Artificial Airways & Ventilation Modes Airways: NPA (used in conscious or unconscious patients) vs. OPA (strictly unconscious patients to avoid vomiting/aspiration). Verify ET tube placement immediately via bilateral breath sounds, symmetric chest movement, and EtCO2 capnography; confirm via chest X-ray (2–3 cm above carina). Cuff Management: Keep cuff pressure at 20–30 cm H2O to prevent aspiration and protect tracheal capillary perfusion. Ventilation Modes: AC (Assist-Control): Preset rate/VT. Spontaneous breaths get full VT; risks hyperventilation and respiratory alkalosis. PC (Pressure Control): Preset pressure; VT varies. Prevents barotrauma in "stiff" or noncompliant lungs. SIMV: Preset rate/VT; spontaneous breaths vary in volume. PSV (Pressure Support): Preset pressure assisting spontaneous breaths; patient controls rate/VT to facilitate weaning. PEEP: Splints open alveoli. High PEEP risks decreased venous return, preload, and cardiac output due to increased thoracic pressure. III. Nursing Interventions & Complications Suctioning: Only PRN (not routinely). Hyperoxygenate with 100% FiO2 before/after; limit passes to <10 seconds. Stop insertion when meeting resistance (carina) to avoid mucosal damage. VAP Prevention: Elevate HOB 30–45 degrees, perform daily SAT/SBT trials, provide oral care with Chlorhexidine, and initiate early mobility. Unplanned Extubation: Stay with the patient, call for help, and manually ventilate with BVM and 100% O2. Accidental Decannulation (Trach <7 days): Spread stoma with hemostat, insert tube with obturator, then remove obturator; if impossible, cover stoma and use BVM over mouth/nose. IV. Chest Tubes & Drainage Systems Water-Seal Chamber: Shows tidaling (water rises on inspiration, falls on expiration). Cessation means lung re-expansion or tube occlusion. Continuous bubbling indicates an air leak. Disconnection: Submerge the distal end in sterile water to re-establish a water seal. Never routinely clamp or strip chest tubes.

• Transcript

CC Nurse | Respiratory Assessment

Gas Exchange: Primary goal: O2/CO2 exchange across alveolar-capillary membrane12. Anatomy: Upper tract warms/humidifies/filters air; epiglottis covers larynx to prevent aspiration3. Carina is highly sensitive, triggering vigorous cough on stimulation3. Aspiration: Right mainstem bronchus is shorter, wider, straighter than left; aspiration is far more common in right lung4. Dead Space: Normal tidal volume ($V_T$) is ~500 mL (~150 mL is anatomical dead space [$V_D$] without gas exchange)2. Alveoli & Surfactant: 300M+ alveoli connect via pores of Kohn2. Surfactant lowers surface tension, preventing collapse (atelectasis)2. Pleural Biology: Visceral pleura lacks pain fibers5; parietal pleura has pain fibers, causing sharp pleuritic pain during inflammation5. Ventilation: Inspiration is active (diaphragm contracts, drawing air in)56; expiration is passive via elastic recoil6. Compliance & Resistance: Compliance decreases in edema, ARDS, fibrosis, and increases in COPD6. Resistance is driven by airway diameter7. Control: Central chemoreceptors (medulla) respond to CSF pH/$H^+$ changes; peripheral receptors respond to low $PaO_2$, low pH, high $PaCO_2$7. COPD may rely on hypoxic drive7. Defense: Alveolar macrophages provide primary defense below bronchioles8. Smoking impairs their phagocytic activity8. Gerontologic & Assessment Key Concepts Aging: Stiffened chest walls, decreased muscle strength, and fewer elastic alveoli cause early airway closure in lung bases (lower $PaO_2$)9. Decreased cilia, cough force, and pharyngeal sensation raise infection/aspiration risks9. Hypoxia Findings: Early signs: restlessness, apprehension, tachycardia, mild hypertension, tachypnea10. Late signs: cyanosis, coma, hypotension, accessory muscle use10. Physical Exam: Fremitus: High in pneumonia/edema (dense); low in COPD, pleural effusion1112. Percussion: Normal resonance11; hyperresonance in air trapping (COPD, pneumothorax)1112; dullness in fluid/consolidation (effusion, pneumonia)1112. Sounds: Bronchial (trachea, 2:3 ratio), Bronchovesicular (scapulae, 1:1), Vesicular (periphery, 3:1)13. High-Yield Diagnostics & Procedures Oximetry: Arterial $SpO_2$ (normal >95%) is inaccurate if <70%, or with cold, hypoperfusion, vasopressors14. Venous $SvO_2/ScvO_2$ (normal 60-80%) tracks $O_2$ supply/demand balance1415. Low values show anemia, low cardiac output, high demand1516. High values (sepsis) signal poor tissue extraction1516. Procedures: Bronchoscopy: Signed consent, NPO 6-12h before, keep NPO after until gag reflex returns17. Thoracentesis: Done sitting upright leaning on table18; post-procedure chest X-ray checks for pneumothorax1718.

• Transcript

CC Nurse | Critical Care Nursing interventions

This episode explains what "CC Nurse" means in regards to the podcasts and the episodes

• Transcript

CC Pharm | Vanc

Vancomycin (Vancocin) 80/20 Clinical Summary 1. Core Profile & Mechanism Class/Action: Glycopeptide bactericidal antibiotic. Mechanism: Binds D-alanyl-D-alanine terminus of peptidoglycan precursors. This inhibits cell-wall synthesis (peptidoglycan polymerase and transpeptidation) and alters permeability, leading to cell death. Also inhibits RNA synthesis. Spectrum: Gram-positive pathogens only (Staphylococci, Streptococci, Enterococci). Killing is concentration-independent, requiring an AUC/MIC ratio ≥ 400 for efficacy. 2. Therapeutic Uses & Route Dichotomy IV Therapy: Septicemia, endocarditis, skin/skin structure, bone/joint, lower respiratory infections, and surgical prophylaxis. Oral Therapy: Strictly for C. difficile-associated diarrhea (CDAD) and S. aureus enterocolitis. Route Dichotomy: Oral bioavailability is extremely low. Oral doses are excreted in feces and cannot treat systemic infections. Oral is strictly for local GI action; IV is strictly for systemic infections. 3. Administration & Reconstitution IV Infusion Rate: Infuse over ≥ 1 hour (10–15 mg/min) to prevent infusion reactions. Loading doses require 2–3 hours. Dilution: Reconstituted vials are diluted with compatible fluids (e.g., D5W, 0.9% NaCl) to 5 mg/mL (up to 10 mg/mL for fluid restriction). Higher concentrations increase reaction risk. Oral Solutions: Injection vials can be compounded in water/syrup for enteral/nasogastric use. Unlabeled Routes: Rectal enemas for CDAD with ileus; preservative-free intrathecal/intraventricular injections for CNS infections. 4. Adverse Effects & Interactions Complications: Nephrotoxicity (renal failure), ototoxicity (hearing loss, tinnitus, vertigo), neutropenia, thrombocytopenia, SJS/TEN, DRESS, and anaphylactoid reactions. Infusion Reaction: Rapid IV infusion causes histamine release, leading to hypotension, dyspnea, flushing, pruritus, and urticaria. Manage by stopping or slowing the infusion. Interactions: Synergistic toxicity with aminoglycosides. Histamine-inducing drugs (ciprofloxacin, opioids, propofol) can hinder desensitization. 5. Monitoring & Interventions (The "20%" Core) Therapeutic Drug Monitoring (TDM): Mandatory for IV therapy. Trough levels of 15–20 mg/L target a therapeutic AUC/MIC of 400–600. Renal Adjustments: Extend IV intervals in renal impairment based on CrCl or SCr to avoid drug accumulation. Key Interventions: Monitor renal function (SCr, BUN), urine output, and auditory symptoms. Assess IV site frequently for phlebitis.

• Transcript

CC Pharm | Digoxin

Lanoxin (Digoxin) 80/20 Clinical Summary 1. Expected Action & Mechanism Positive Inotrope: Inhibits the Na+/K+-ATPase pump1, raising intracellular sodium. This reverses sodium-calcium exchange to increase intracellular calcium, boosting myocardial contractility, force, and velocity12. Negative Chrono/Dromotrope: Increases vagal activity, slowing AV nodal conduction and prolonging refractory period to slow ventricular rate3. 2. Therapeutic Use & Selection Indicated for heart failure (HF) and controlling ventricular rate in chronic atrial fibrillation (AF)4. Off-label for fetal supraventricular tachyarrhythmias5. Benefit: Boosts cardiac output, lowers sympathetic tone/heart rate, and causes diuresis2. Beta-blockers, verapamil, and diltiazem are replacing it for AF rate control13. Does not convert acute AF to sinus3. 3. Crucial Administration Protocols IV: Preferred (IM causes severe pain)67. Dilute 1 mL in $\ge$4 mL sterile water, 0.9% NaCl, or D5W to prevent precipitation8. Inject slowly over $\ge$5 minutes to avoid sudden vasoconstriction8. Oral (PO): Tablet bioavailability is 60–80% (solution 70–85%)910. High-fiber meals decrease absorption910. 4. Dosing & Renal Safety Guidance Dosing must be based on lean body weight (LBW), efficacy, and serum levels4. Geriatric: PIM (avoid first-line); if used, limit to 125 mcg/day to reduce toxicity risk1112. Renal GFR Adjustments (Half-life 36–48h)13: >50 mL/min: No adjustment14. 10–50 mL/min: Give 25%–75% of dose every 36h14. <10 mL/min: Give 10%–25% of dose every 48h14. Dialysis: Not removed by dialysis15. 5. Adverse Reactions & Toxicity Severe Risks: AV block, bradycardia, VT/VF, cardiac arrest, hyperkalemia, bowel ischemia/necrosis1617. Toxicity Signs: Blurred/yellow vision (xanthopsia), GI distress (nausea, vomiting, anorexia), and CNS changes (confusion, delirium, hallucinations)16more_horiz. 6. Priority Nursing Pearls (The 20% to Know) Monitoring: Track heart rate (bradycardia risk)16, toxicity, and clinical efficacy4. Labs: Monitor GFR/CrCl, potassium (hypokalemia is an adverse reaction; hyperkalemia occurs in toxicity), and digoxin levels16more_horiz. Interactions: Digoxin is a P-gp substrate; P-gp inhibitors/inducers trigger drug interactions13. WPW use increases ventricular response risk4.

• Transcript

CC Pharm | Albuterol

Description & Key Indications: Albuterol is a short-acting beta-2 agonist (SABA) used as an inhaled bronchodilating agent. It treats acute bronchospasm and episodic wheezing in asthma, exercise-induced bronchospasm (EIB) prophylaxis, and serves as reliever therapy in COPD. Off-label uses include hyperkalemia, where it lowers potassium by 1–1.5 mEq/L, and managing respiratory symptoms in anaphylaxis unresponsive to epinephrine. Inhaled albuterol is preferred over oral routes due to its superior side-effect profile and faster onset. Mechanism of Action: As a racemic mixture, bronchodilation is driven by the R-isomer (levalbuterol); the S-isomer exhibits bronchoconstrictive properties in animals. Albuterol stimulates moderately selective beta-2 receptors, activating adenylate cyclase to increase intracellular cyclic AMP. This triggers protein kinase A, inhibiting myosin phosphorylation and lowering calcium to relax bronchial smooth muscle. It also inhibits mast cell degranulation and drives potassium intracellularly via the Na/K ATPase pump. Crucial Safety & Adverse Effects: Inhalation avoids many systemic issues, but severe reactions can occur, including paradoxical bronchospasm, arrhythmia, atrial fibrillation, Stevens-Johnson syndrome, and anaphylactoid reactions. Common mild-to-moderate effects include tremors (to 37.9%), infections (to 21%), headaches, rhinitis, tachycardia, palpitations, hypokalemia, and excitability. Remaining 80% (Administration, Dosages & Pharmacokinetics) Administration Techniques: Inhalation methods include metered-dose inhalers (MDIs), dry powder inhalers (DPIs), and nebulizers. MDIs require shaking, priming, and slow inhalation, followed by a 10-second breath hold; spacers or valved holding chambers (VHC) are recommended for pediatric and uncoordinated patients. For pediatric acute asthma, MDI with a VHC is as effective as nebulization. DPIs (e.g., RespiClick) are breath-activated upon opening the cap and must remain dry at all times. Nebulized solution is delivered over 5 to 15 minutes; "blow-by" is discouraged. Dosing Standards: For acute asthma exacerbations, adults and children age 6 and older inhale 360–900 mcg via MDI every 20 minutes for the first hour, then every 1 to 4 hours as needed. EIB prophylaxis requires 180 mcg inhaled 15–30 minutes before exercise. Oral doses range from 2–4 mg 3–4 times daily, but guidelines discourage this route due to slow onset and systemic side effects. Pharmacokinetics: Inhaled albuterol works within 5–15 minutes, peaks in 0.5–2 hours, and lasts 2–6 hours, with 90% of the dose typically swallowed. Oral immediate-release onset is 30 minutes, lasting 4–6 hours, while extended-release lasts 8–12 hours. Metabolism is hepatic, and excretion is primarily renal.

• Transcript

CC Pharm | Dopamine

Dose-Dependent Mechanism: Dopamine is a metabolic precursor to norepinephrine. Clinical effects depend entirely on the infusion rate: Low Dose (< 5 mcg/kg/min): Stimulates dopaminergic D1 and D2 receptors in renal, mesenteric, coronary, and cerebral beds, causing vasodilation and increasing blood flow. Intermediate Dose (5 to 10 mcg/kg/min): Stimulates dopaminergic and beta-1-receptors, increasing cardiac contractility, chronotropy, and mildly raising systemic vascular resistance. High Dose (> 10 mcg/kg/min): Stimulates alpha-receptors, causing potent vasoconstriction. Rates > 20 mcg/kg/min frequently cause arrhythmias or severe vasoconstriction. Key Indications: Dopamine provides hemodynamic support in distributive shock (e.g., septic, cardiogenic, anaphylactic, neurogenic), open-heart surgery, or renal failure. It is used for symptomatic bradycardia unresponsive to atropine or pacing, and post-cardiac arrest hypotension. It can provide short-term inotropic support in acute/chronic heart failure. Black Box Warning (Extravasation): Extravasation can cause severe tissue necrosis. Dopamine must be infused into a large vein (e.g., antecubital fossa). If extravasation occurs, immediately infiltrate the area with 10 to 15 mL of 0.9% NaCl containing 5 to 10 mg of phentolamine using a fine needle. The Supporting 80% (Operational Details) Administration & Incompatibilities: Correct hypovolemia before starting. Dilute concentrate in compatible solutions (e.g., 5% Dextrose, 0.9% NaCl) to 200–1,600 mcg/mL (standard adult infusions use 1,600 or 3,200 mcg/mL). It is completely inactivated in alkaline solutions; never add to Sodium Bicarbonate. Do not run dextrose-containing dopamine through the same line as blood to prevent hemolysis. Monitor urine flow, cardiac output, and blood pressure. Dosing: Adults: Initially 2 to 5 mcg/kg/min, titrating by 5 to 10 mcg/kg/min (Max: 50 mcg/kg/min). Pediatrics (Neonates to Adolescents): Initially 1 to 5 mcg/kg/min, titrating by 2.5 to 5 mcg/kg/min (Max: 15 to 20 mcg/kg/min). Pharmacokinetics: Administered via IV or intraosseously (during CPR). Onset is within 5 minutes, persisting under 10 minutes, with a 2-minute plasma half-life. It does not cross the blood-brain barrier significantly and is metabolized in liver, kidneys, and plasma by MAO and COMT. About 25% is converted to norepinephrine. Excreted in urine.

• Transcript

CC Pharm | Piperacillin/ Tazo [Zosyn]

Zosyn (Piperacillin/Tazobactam) 80/20 Clinical Summary Core Classification & Mechanism Drug Class: Zosyn is an injectable combination of piperacillin (extended-spectrum penicillin) and tazobactam (beta-lactamase inhibitor). Bactericidal Action: Piperacillin binds to penicillin-binding proteins (PBPs), inhibiting cell wall synthesis and causing autolysin-mediated lysis. Beta-Lactamase Protection: Tazobactam is an irreversible inhibitor of beta-lactamases (Sykes types II–V, staphylococcal penicillinase, and ESBLs), shielding piperacillin. Pharmacodynamics: Exhibits time-dependent (concentration-independent) killing, relying on time free drug levels remain above the pathogen's MIC. Pharmacokinetics & Delivery Administration: Given via IV infusion over at least 30 minutes or via extended (4-hour) / continuous (24-hour) infusions. It is not FDA-approved for IV push. Distribution: Widely distributed in tissues (50–100% of plasma); both drugs are ~30% protein-bound. Elimination: Cleared unchanged in urine (68% piperacillin, 80% tazobactam) via tubular secretion/glomerular filtration. Half-life is 0.7–1.5 hours in normal renal function. High-Yield Indications & Adult Dosing Skin/Skin Structure: 3.375 g IV every 6 to 8 hours (for 5 to 14 days). Intra-abdominal: 3.375 g IV every 4 to 6 hours or 4.5 g IV every 6 hours. Nosocomial Pneumonia: 4.5 g IV every 6 hours (for 7 to 14 days). Sepsis/Bacteremia & Febrile Neutropenia: 4.5 g IV every 6 hours. Renal & Hepatic Adjustments Hepatic Impairment: No dose adjustment needed. Renal Impairment (Conventional Adult Dosing): CrCl > 40 mL/min: No adjustment. CrCl 20 to 40 mL/min: Nosocomial pneumonia reduced to 3.375 g every 6 hours; other indications reduced to 2.25 g every 6 hours. CrCl < 20 mL/min: Nosocomial pneumonia reduced to 2.25 g every 6 hours; other indications reduced to 2.25 g every 8 hours. Hemodialysis: Max 2.25 g every 8 hours (pneumonia) or 12 hours (others); give a 0.75 g to 1.125 g supplemental dose post-dialysis as 30–40% is cleared. Key Safety & Adverse Reactions Common: Diarrhea (11.3–20.0%), headache, nausea (5.8–6.9%), and constipation (7.7–8.4%). Severe Risks: Anaphylactic shock, acute renal failure, seizures, and C. difficile-associated diarrhea. Hematologic Warnings: Leukopenia, thrombocytopenia, platelet dysfunction, and prolonged bleeding times. Cutaneous Reactions: Stevens-Johnson syndrome, TEN, and DRESS.

• Transcript

CC Pharm | Amiodarone

Amiodarone (Cordarone) Clinical 80/20 Summary 1. Mechanism & Physiological Effects (The 20% Science) Multiclass Action: Class III antiarrhythmic (potassium blocker delaying phase 2/3 repolarization and prolonging refractory period). Also exhibits Class I (sodium blockade slowing phase 0), Class II (noncompetitive alpha/beta-blockade), and Class IV (calcium blockade) properties. Hemodynamics: Relaxes smooth/cardiac muscle, decreasing peripheral/coronary vascular resistance and afterload, reducing myocardial oxygen demand (MVO2). 2. Clinical Uses & Key Dosing Ventricular Arrhythmias (ACLS): For pulseless VF/VT: 300 mg IV/IO push, then 150 mg if refractory. Stable VT / Wide-Complex Tachycardia: 150 mg IV over 10 min, then 1 mg/min for 6 hours, then 0.5 mg/min maintenance. Atrial Fibrillation/Flutter (Off-Label): Rate control and conversion. Oral Dosing: Slow absorption and massive tissue distribution require large loading (800–1600 mg/day for 1–3 weeks) before maintenance of 200–400 mg/day. 3. Critical Toxicities & Warnings (The High-Risk 20%) Pulmonary Toxicity: Fatal pneumonitis or alveolar/pulmonary fibrosis (up to 17% incidence; 10% mortality). Monitor baseline and regular PFTs and chest X-rays. Hepatotoxicity: Can cause severe liver injury. Monitor transaminases; hold or reduce dose if LFTs exceed 3x upper limit of normal. Thyroid Dysfunction: Amiodarone is 37% iodine by weight and blocks T4-to-T3 conversion. Can cause hypo- or hyperthyroidism (thyrotoxicosis). Monitor TSH. Cardiotoxicity: Bradycardia, AV blocks, and QT prolongation leading to Torsade de Pointes. Contraindicated in sick sinus syndrome and 2nd/3rd-degree block without a pacemaker. Ocular/Dermatologic: Corneal microdeposits (common), photosensitivity, and blue-gray skin discoloration. 4. Nursing & Administration Pearls Infusion Safety: Concentrations >2 mg/mL cause severe phlebitis; use a central line for infusions >1 hour. Always use an in-line filter and volumetric pump. Incompatibility: Adsorbs to PVC (dosing accounts for this) and leaches toxic DEHP plasticizers from PVC tubing. Use glass or polyolefin containers for infusions >2 hours. Pharmacokinetics: Highly lipophilic; volume of distribution is ~70 L/kg. Terminal half-life averages 53 days (range 26–107 days). Effects and interactions (inhibits CYP3A4, CYP2C9, P-gp) persist for months after stopping. Client Education: Take consistently with/without food. Report new dyspnea or cough immediately. Wear sunscreen. Follow up for ophthalmic, thyroid, and liver testing.

• Transcript

CC Pharm | Epinephrine

Epinephrine is a potent, nonselective adrenergic agonist acting on alpha-1, alpha-2, beta-1, and beta-2 receptors. This high-yield 80/20 summary covers the essential clinical and exam concepts: 1. Expected Pharmacological Action & Mechanism Alpha-1 activation causes arteriolar vasoconstriction. Beta-1 activation induces positive inotropic and chronotropic responses, increasing cardiac workload and coronary vasodilation. Beta-2 activation drives bronchodilation, skeletal muscle vasodilation, and hepatic glycogenolysis. Alpha-2 activation inhibits insulin release and provides negative feedback on norepinephrine. Actions are mediated by cyclic AMP (increased by beta, decreased by alpha). 2. Clinical Indications & Route Optimization Anaphylaxis: Drug of choice. Intramuscular (IM) injection in the anterolateral thigh (vastus lateralis) is preferred because absorption is rapid and complete. Subcutaneous (SQ) absorption is delayed and variable, making it not routinely recommended. Cardiac Arrest: Administer 1 mg IV or IO every 3 to 5 minutes. Do not interrupt CPR to administer. Flush with 0.9% NaCl to promote central entry. Hemodynamic Support: Continuous IV infusion at 0.01 to 2 mcg/kg/min. Low doses (<0.3 mcg/kg/min) favor beta-effects (tachycardia, inotropy, decreased SVR), while higher doses (>0.3 mcg/kg/min) cause alpha-vasoconstriction. Endotracheal (ET): Used only if IV/IO is delayed. Requires higher doses (e.g., 2 to 2.5 mg in adults) and is associated with lower drug levels and survival. 3. Safety, Administration & Nursing Interventions Extravasation Antidote: Extravasation causes severe ischemia and tissue necrosis. Avoid peripheral leg veins in the elderly. Immediately infiltrate the cold, pale area with phentolamine (5 to 10 mg in 10 to 15 mL saline for adults). Incompatibilities: Epinephrine is inactivated in alkaline solutions and is incompatible with sodium bicarbonate. Protect from light; discard if cloudy, pinkish, or brownish. Metabolic Tracking: Monitor for transient hyperkalemia followed by hypokalemia (due to potassium uptake into skeletal muscles), and hyperglycemia (due to insulin inhibition and glycogenolysis). Complications: Watch for severe reactions including stroke, myocardial infarction, ventricular fibrillation/tachycardia, pulmonary edema, and severe hypertension.

• Transcript

CC Pharm | Propofol

Clinical Action & Pharmacokinetics Mechanism: Propofol is an IV anesthetic/sedative that enhances GABAA currents by slowing deactivation and reducing receptor desensitization. It also inhibits NMDA glutamate receptors, depressing excitatory transmission, and exerts antiemetic effects by reducing serotonin in the area postrema. Pharmacokinetics: Follows a 3-compartment linear model. Onset is rapid (~40s) via quick blood-brain equilibration. Clearance is 23–50 mL/kg/min via hepatic conjugation to inactive metabolites excreted by kidneys. Distribution accounts for 50% of plasma decline. Infusions over 10 days accumulate in fat, extending terminal half-life to 1–3 days and delaying recovery. Critical Administration & Dosing Rules Safe Handling: It is a single-use product; maintain strict aseptic technique. Discard unused propofol or tubing within 12 hours of opening, or within 6 hours if mixed with lidocaine. Do not administer Fresenius Propoven via a microbiological filter. Induction Dosing (IV): Healthy Adults (18–64): 2 to 2.5 mg/kg IV titrated to response. Geriatric/Debilitated/ASA III/IV: 1 to 1.5 mg/kg IV. Pediatric (3–16): 2.5 to 3.5 mg/kg IV. Maintenance & ICU Sedation: Anesthesia Maintenance: 50 to 100 mcg/kg/min continuous IV infusion after a 150–200 mcg/kg/min loading phase. ICU Sedation (Ventilated Adults): Start at 5 mcg/kg/min; titrate by 5–10 mcg/kg/min every 5–10 minutes (usual range: 5–50 mcg/kg/min). Do not exceed 4 mg/kg/hour unless benefits outweigh risks. Discontinuation: Avoid abrupt withdrawal to prevent rapid awakening, anxiety, and ventilator resistance; maintain light sedation until 10–15 minutes before extubation. Pain Reduction: Administer via larger veins, or add IV lidocaine (up to 20 mg per 200 mg propofol) immediately before injection. Major Safety Warnings & Complications Provider Requirements: Administer only by clinicians trained in general anesthesia or critical care, with immediate access to airway, ventilation, and resuscitation equipment. Lock/manage inventory to prevent diversion. Adverse Reactions: Cardiovascular & Respiratory: Hypotension is highly common (3% to 26%). Other risks include bradycardia (1% to 3%), apnea (1% to 3%), respiratory depression, hypoxia, and pulmonary edema. PRIS: Prolonged, high-dose infusions for ICU sedation are associated with Propofol-Related Infusion Syndrome (PRIS), causing fatal metabolic derangements and organ failure. EUA Warning: Fresenius Propoven 2% is double the strength (20 mg/mL) of standard FDA-approved 1% (10 mg/mL). Exercise extreme caution with pump settings to prevent overdose.

• Transcript

CC Pharm | Norepinephrine

Norepinephrine (Levophed) 80/20 Summary Action & MOA: Direct α-agonist causing potent vasoconstriction. Modest β1​ activity triggers cardiac stimulation at lower doses; vasoconstriction dominates at higher doses. Elevated SVR triggers reflex vagal bradycardia (slowing HR). Coronary flow increases without raising myocardial oxygen demand. Uses: First-line for septic shock, sepsis, acute hypotension, cardiogenic shock. Alternative in hepatorenal syndrome (with albumin). Complications: Tissue necrosis (extravasation), bradycardia, lactic acidosis, pulmonary edema, hypertension, and local hypoxia. Administration & Dilution: Dilution: Standard: 4mg in 1,000mL. Preferred: D5W/D5NS (dextrose protects against oxidation). Saline alone stable up to 16mcg/mL, though FDA discourages. Adult standard: 16, 32, 128mcg/mL. Incompatibility: Do not mix with alkaline solutions (e.g., bicarb). Reject if pinkish/discolored or has precipitate. Route: Large vein infusion; transition to central line ASAP. Avoid leg veins in elderly. Monitoring: BP every 2 mins initially, then every 5 mins. Check site frequently for free flow/extravasation. Weaning: Reduce rate gradually; avoid abrupt withdrawal to prevent rebound hypotension. Extravasation Antidote: Infiltrate ASAP (within 12h) with phentolamine 5-10mg in 10-15mL NS. Pharmacokinetics: Onset <30s; steady-state 5 mins; duration <10 mins. Half-life ~2.4 mins; metabolized by COMT/MAO. Why Choose It? Preferred in septic shock; raises MAP/SVR with less tachycardia than dopamine, sparing oxygen demand. Final 80/20 Review The 20% to Absolutely Know: Hypovolemia First: Correct fluid deficit before starting norepinephrine. Central Line Priority: Transition to central line ASAP to mitigate necrosis risk. Phentolamine for Extravasation: Immediate local infiltration reverses ischemia. Dextrose Over Saline: Dextrose-containing diluents prevent oxidation. Incompatible with Bicarb: Inactivated in alkaline solutions. If I Remember Nothing Else: Norepinephrine is the first-line vasopressor for septic shock. With a <30s onset and 2.4m half-life, it requires continuous infusion, BP checks every 2–5 mins, and gradual weaning. Monitor the IV site continuously; treat extravasation with immediate phentolamine infiltration to prevent necrosis.

• Transcript

CC Pharm | Vasopressin

Vasopressin (Vasostrict) Clinical Reference 1. Action: Exogenous ADH analog. Promotes renal water reabsorption via cAMP. Directly contracts vascular smooth muscle non-adrenergically. 2. Use: Raising BP in vasodilatory shock refractory to fluids/catecholamines; post-op abdominal distention. 3. Complications: Cardiac arrest, bradycardia, MI, AFib, water intoxication, severe hyponatremia, necrosis. 4. Admin: IV infusion must go through central vein. If peripheral, use >=20G catheter & check frequently. Premixed (0.4/0.6 units/mL) needs no dilution. Dilute 20 units/mL to 0.1 or 1 unit/mL in NS/D5W. Discard after 18h room temp, 24h refrigerated. IM/SC duration is 2-8h; IO used in CPR. 5. Contraindications: No renal/hepatic adjustments needed. Caution in coronary artery disease (ischemia risk). 6. Nursing: Monitor ECG, BP, fluids, sites. For extravasation, inject 5-10 mg phentolamine directly. 7. Interactions: Muscle contraction not blocked by adrenergic blockers/denervation. No CYP450 interactions. 8. Education: ICU drug; explain central line need and to report chest pain or IV burning. 9. Evaluation: Increased MAP, catecholamine-sparing, stable sodium/osmolality. 10. Why Choose? Bypasses catecholamine resistance. Onset peaks <15 min; fades <20 min of stopping. 11. Pearls: Most Dangerous: MI, tissue necrosis. Key Lab: Serum sodium (detects hyponatremia). Antidote: Phentolamine 5-10 mg for extravasation. NCLEX/ATI: Run through central line to prevent necrosis. 12. Scenario: Septic shock patient hypotensive on norepinephrine. Adding vasopressin raises MAP, allowing down-titration of toxic catecholamines. 13. Mnemonic: Vasopressin Presses Vessels (V1 constriction) & Preserves Volume (V2 reabsorption). THE 20% I ABSOLUTELY NEED TO KNOW Catecholamine-Saver: Works on non-adrenergic receptors, maintaining potency in severe acidotic shock where catecholamine receptors are down-regulated. Extravasation Rescue: High necrosis risk peripherally. Immediately inject 5-10 mg phentolamine to site if extravasation occurs. Water Retention: Exogenous ADH action causes renal water retention, causing dilutional hyponatremia/water intoxication. IF I REMEMBER NOTHING ELSE Direct non-adrenergic vasoconstrictor with strong catecholamine-sparing effect. IV onset peaks <15 min; pressor effects fade <20 min of stopping. Central line infusion preferred; extravasation causes severe skin necrosis. Phentolamine (5-10 mg) is the antidote for local extravasation. Conserves free water; monitor closely for hyponatremia. No hepatic or renal dosage adjustments are required.

• Transcript

CC PHARM [RSI] | Vecuronium

Vecuronium is an intermediate-acting, nondepolarizing neuromuscular blocking agent used for skeletal muscle relaxation during surgery, mechanical ventilation, and endotracheal intubation, including rapid-sequence intubation (RSI). 1. Critical Safety & Boxed Warning (The Vital 20%) Respiratory Paralysis: Causes respiratory paralysis (potentially fatal). Administer only by experienced clinicians in settings with immediate intubation, ventilation, oxygen, and reversal agents. Induction Prerequisite: To prevent extreme distress, vecuronium must only be administered after unconsciousness is induced with adequate amnesia, sedation, and analgesia. Storage Warning: Due to risk of fatal accidental administration, store vials with cap/ferrule intact and separated from other drugs to prevent selection errors. 2. Mechanism of Action & Pharmacokinetics Mechanism: Competes with acetylcholine (ACh) for receptors at the motor end-plate. Paralysis progresses predictably: fine muscles (eyes, face, neck) first, then limbs, chest, abdomen, and lastly the diaphragm. Recovery occurs in reverse order. Onset & Duration: IV administration acts within 1 minute, peaks at 3 to 5 minutes, and lasts 25 to 40 minutes. Metabolism & Elimination: 60% to 80% protein-bound. Active 3-desacetyl metabolite has 50% to 70% potency of parent compound. Elimination half-life: 65 mins (infants), 41 mins (children), and 65 to 75 mins (adults). 3. Core Clinical Dosing Rapid-Sequence Intubation (RSI): Adults: 0.1-0.2 mg/kg IV (onset 2-4 mins). Pediatrics (7 weeks to 17 years): 0.15-0.2 mg/kg IV (onset 2.5-3 mins). Neonates (<7 weeks): 0.1 mg/kg IV (onset 2.5-3 mins). Mechanical Ventilation & Surgery: Adults: 0.08-0.1 mg/kg initial IV bolus, then 0.01-0.015 mg/kg every 12-15 mins as needed, or continuous infusion of 0.8-1.7 mcg/kg/min. Defasciculation: 0.01 mg/kg IV given 1-3 mins before succinylcholine in adults. Rare in pediatrics. 4. Reconstitution & Stability Reconstitution: Add 10 or 20 mL of Bacteriostatic Water to 10 or 20 mg vials (1 mg/mL). For neonates, use Sterile Water to avoid benzyl alcohol toxicity. Storage: Bacteriostatic water reconstitution lasts 5 days (room temp/refrigerated); Sterile Water is single-use and discarded within 24 hours. Do not mix with alkaline solutions. 5. Monitoring & Adverse Effects Monitoring: Use a peripheral nerve stimulator to monitor response (target: 1 to 2 twitches). Adverse Reactions: Major risks include bronchospasm, anaphylaxis, acute myopathy, prolonged paralysis, tachycardia, and hypotension. Minimal histamine release occurs. 📊 I can generate a quick reference dosing card or a cheat sheet comparing these pediatric vs. adult infusion rates for your clinical review.

• Transcript

NURSE | Know Your Specialty

pick your specialty that you want to get into, learn the certs you need for them and go for it.

• Transcript

CC Pharm [RSI] | Succinylcholine

Succinylcholine is a short-acting, depolarizing neuromuscular blocking agent (NMBA) used as an adjunct to general anesthesia to facilitate tracheal intubation and provide skeletal muscle relaxation. Applying the 80/20 rule, the core clinical essence of succinylcholine centers on its rapid mechanism, critical safety warnings, and precise dosing. 1. Core Mechanism & Pharmacokinetics (The "20%" Driving Action) Mechanism: Succinylcholine competes with acetylcholine (ACh) at cholinergic receptors on the motor end-plate, depolarizing the membrane. Resistant to acetylcholinesterase, it remains bound to inhibit repolarization, causing transient muscle fasciculations followed by flaccid paralysis. Paralysis Order: Affects facial and glottis muscles first, then intercostals, diaphragm, and other skeletal muscles. Recovery occurs in the reverse order. Pharmacokinetics: Highly ionized with low lipid solubility, it distributes rapidly in extracellular space. It is hydrolyzed by plasma cholinesterase to inactive metabolites. Prolonged Blockade: Decreased plasma cholinesterase activity—due to genetics, liver/renal dysfunction, pregnancy, burns, or drugs (e.g., oral contraceptives)—prolongs neuromuscular blockade. 2. Boxed Warnings & Life-Threatening Risks (Critical Safety "80%") Severe Hyperkalemia: Contraindicated after the acute phase of major burns, multiple trauma, skeletal muscle denervation, or upper motor neuron injury. It can trigger severe hyperkalemia, peaking 7 to 10 days post-injury, causing cardiac arrest. Avoid if baseline potassium is > 5.5 mEq/L. Pediatric Safety: Contraindicated in patients with skeletal muscle myopathy (e.g., Duchenne's). Reserve pediatric use for emergency intubation due to risks of rhabdomyolysis and sudden hyperkalemic cardiac arrest (often presenting as peaked T-waves). Malignant Hyperthermia (MH): Contraindicated in patients with genetic susceptibility (RYR1 or CACNA1S variants). Inhalation anesthetics compound this risk. Continuous ETCO2 and temperature monitoring are vital for early recognition. 3. Key Clinical Dosing & Administration Rapid-Sequence Intubation (RSI): Adults: 1.5 mg/kg IV (onset ~1 min). Pediatrics (2-17 years): 1 to 1.5 mg/kg IV. Infants & Neonates: 2 mg/kg IV. Non-Emergent Intubation: Adults: 0.6 mg/kg IV (range: 0.3 to 1.1 mg/kg). Intramuscular (IM) Backup: Used if IV access is unavailable. Adults: 3 to 4 mg/kg (Max: 150 mg); Infants/Children: 4 to 5 mg/kg IM. Onset is 2 to 5 minutes. Incompatibilities: Succinylcholine is acidic (pH 3 to 4.5); do not mix with alkaline solutions (pH > 8.5).

• Transcript